| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2fc1c2defef6a8fca29185615c572d5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df6477c6510b1b839ec3dcfcdb07cd2e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-40 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6847
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6425 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 |
| filingDate |
2014-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b88f84bc4dcb5c86685577464c99fadd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5f35312ad5d8a528041b606bb77031c |
| publicationDate |
2018-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9861711-B2 |
| titleOfInvention |
Labeled ligands of anti-Mullerian hormone for diagnosis of endometriosis |
| abstract |
The present invention relates to isolated ligands of anti-Mullerian hormone marked so as to be directly detectable by means of magnetic resonance imaging in the endometriosic lesions. In particular, such ligands can be used in a method for diagnosing in vivo endometriosis wherein said method comprises a passage of localizing and/or evaluating the entity of the endometriosic lesions in a patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023166305-A1 |
| priorityDate |
2013-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |